Developing General Practice and Web-Based Toolkits for the Familial Hypercholesterolaemia (FH) Case Ascertainment Tool (FAMCAT)

Similar documents
West Midlands Familial Hypercholesterolaemia Service

Identification and management of familial hypercholesterolaemia (FH) - An overview

The identification and management of heterozygous familial hypercholesterolaemia in adults, young people and children (QS41)

Familial hypercholesterolaemia

Appendix F Simon Broome Diagnostic criteria for index individuals and relatives

Cost effectiveness of cascade testing for FH:

Costing report: Lipid modification Implementing the NICE guideline on lipid modification (CG181)

National Clinical Audit of the Management of Familial Hypercholesterolaemia 2010

SMASH! The Salford Medication Safety Dashboard. Richard Williams. NIHR Greater Manchester Patient Safety Translational Research Centre

Appendix E Health Economic modelling

Familial Hypercholesterolaemia: Finding FH and Primary Prevention. Rob Gingell FH Specialist Nurse (North Wales)

Focus on FH (Familial Hypercholesterolemia) Joshua W. Knowles, MD PhD for PCNA May, 2013

The reduced cost of providing a nationally recognised service for familial hypercholesterolaemia

FACT SHEET 53. What is inherited predisposition to cardiovascular disease?

Prescribing Policy: Lipid Modification - Primary Prevention

National End of Life Care Intelligence Network

The antibiotic crisis: Is there a role for traditional herbal remedies?

APPENDIX 2F Management of Cholesterol

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Low-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies

Coronary heart disease and stroke

Volume 2; Number 11 July 2008

rosuvastatin, 5mg, 10mg, 20mg, film-coated tablets (Crestor ) SMC No. (725/11) AstraZeneca UK Ltd.

ACC/AHA GUIDELINES ON LIPIDS AND PCSK9 INHIBITORS

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

Setting The setting was primary care. The economic study was carried out in the United Kingdom.

Proprotein Convertase Subtilisin/Kexin type 9(PCSK9) Inhibitors Prior Authorization with Quantity Limit Program Summary

The Addition of Ezetimibe to Statin therapy in. Patients with Homozygous Familial. Hypercholesterolaemia

Request for Prior Authorization for PCSK9 inhibitor therapy Website Form Submit request via: Fax

Familial Hypercholesterolemia

Should we base treatment decisions on short-term or lifetime CVD risk? Rod Jackson University of Auckland New Zealand

Understanding new international guidelines to tackle CV Risk: A practical model John Deanfield, MD UCL, London United Kingdom s

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

Dr Anne King dc life dclife.co.uk

Independent computerised aphasia therapy at home:

Cost effectiveness analysis of different approaches of screening for familial hypercholesterolaemia

Community Based Diabetes Prevention

NHS England Diabetes Programme Update June 2018

Familial hypercholesterolaemia in children and adolescents

Making connections. Bilateral Cochlear Implant Audit

2017 Cardiovascular Summit for Primary Care Thursday 30th & Friday 31st March Crowne Plaza, Dublin

HDL-C. J Jpn Coll Angiol, 2008, 48: NIPPON DATA80, MEGA study, JELIS, dyslipidemia, risk assessment chart

Lipid Lowering in patients with High Risk of Cardiovascular Disease (Primary Prevention)

Elements for a public summary

People living well with Dementia in the East Midlands: Improving the Quality of Care in Acute Hospitals

Early Clinical Development #1 REGN727: anti-pcsk9

NIHR Supporting collaboration in life sciences research

Appendix E Health Economic modelling

An update on lipidology and cardiovascular risk management. Lipids, Metabolism & Vascular Risk Section - Royal Society of Medicine

Tackling atrial fibrillation the health economics evidence

Inhibition of PCSK9: The Birth of a New Therapy

Russian research program evaluating the extent of underdiagnosed and undertreated of familial hypercholesterolaemia in the population.

LIPID CLUB Rome, 2014

A primary care response to domestic abuse from research to mainstream: the IRIS story. Gene Feder. Domestic abuse summit 2018 London 4 th May 2018

New Guidelines in Dyslipidemia Management

PCSK9 Inhibition: From Genetics to Patients

Exercise for Falls Prevention in Older People: Whole System Approaches. Daniel MacIntyre, Population Health Services Manager, PHE

DIAGNOSIS AND TREATMENT OF FH CHILDREN. O. GUARDAMAGNA Dipartimento di Scienze della Sanità Pubblica e Pediatriche UNIVERSITA DI TORINO

Saving Lives, Saving Families: The health, social and economic advantages of detecting and treating familial hypercholesterolaemia (FH)

From Population Studies to Clinical Trials

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

A Mendelian Randomized Controlled Trial of Long Term Reduction in Low-Density Lipoprotein Cholesterol Beginning Early in Life

Evidence Briefing for NHS Bradford and Airedale. Physical health monitoring for people with schizophrenia or other serious mental illness

SECONDARY PREVENTION OF CORONARY HEART DISEASE AND ISCHAEMIC STROKE/TIA

LIST OF ABBREVIATIONS

Statins and Cholesterol. Noreen Devanney Primary Care Pharmacist Surrey Heath CCG

NHS ENGLAND BOARD PAPER

Primary Prevention Patients aged 85yrs and over

Proof of Concept: NHS Wales Atlas of Variation for Cardiovascular Disease. Produced on behalf of NHS Wales and Welsh Government

Familial Hypercholesterolemia What a cardiologist should know

The diagnostic accuracy of school hearing screening tests and cost-effectiveness of school entry hearing screening programmes

Cheshire & Merseyside Cardiovascular Programme

A Naturally Randomized Trial Comparing the Effect of Genetic Variants that Mimic CETP Inhibitors and Statins on the Risk of Cardiovascular Disease.

The cost-effectiveness of a new statin (rosuvastatin) in the UK NHS Palmer S J, Brady A J, Ratcliffe A E

NHS Diabetes Programme

What can the NHS do to reduce premature mortality? Professor Sir Mike Richards NHS Health Check National Learning Event April 2013

Getting serious about preventing cardiovascular disease

Low-density lipoprotein as the key factor in atherogenesis too high, too long, or both

Managing Dyslipidemia and ASCVD Risk: Confusion, Controversy Consensus

*Carbohydrate & Lipid Metabolism Research Unit, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa

Lipids What s new (and what s not)

Southern Derbyshire Shared Care Pathology Guidelines. Dyslipidaemia

Role of Genetic Counseling in FH: What Referring Physicians Need to Know. Amy C. Sturm, MS, CGC September 21, 2013

Lipids explained. 1 Patient understanding. Time out. Abstract

Dyslipidemia and Combination Therapy: A Framework for Clinical Decision Making

HoFH presents with a wide spectrum of LDL-C levels in a genetically confirmed cohort of patients

THE CLINICAL BIOCHEMISTRY OF LIPID DISORDERS

BEST PRACTICE MANAGEMENT: CARDIOVASCULAR RISKS

INTERNATIONAL LIPOPROTEIN STANDARDIZATION FORUM Fasting Time and Lipid Levels in a Community-Based Population: A Crosssectional

Your Health Topic : Genomics and Clinical Practice How genetics is improving care for patients

ESC/EAS Guidelines for the Management of Dyslipidaemias

private patients centre Royal Brompton Heart Risk Clinic

Setting The study setting was secondary care. The economic analysis was conducted in the UK.

REPATHA (PCSK9 INHIBITORS)

Cardiovascular Disease Prevention: Current Knowledge, Future Directions

GOVERNING BODY REPORT

Peripheral Arterial Occlusive Disease- The Challenge in patients with diabetes

In 2008 NICE issued guidelines on lipid modification. Key points are summarised below.

The number of patients waiting on the pancreas transplant list fell by 7% during the year, to 252 at 31 March 2015

Considerations and Controversies in the Management of Dyslipidemia for ASCVD Risk Reduction

Transcription:

Developing General Practice and Web-Based Toolkits for the Familial Hypercholesterolaemia (FH) Case Ascertainment Tool (FAMCAT) Dr Stephen Weng NIHR Research Fellow NIHR School for Primary Care Research University of Nottingham School for Primary Care Research The National Institute for Health Research School for Primary Care Research (NIHR SPCR) is a partnership between the Universities of Bristol, Cambridge, Keele, Manchester, Newcastle, Nottingham, Oxford, Southampton and University College London.

What is FH? Inherited autosomal dominant disease (PCSK9, APOB, LDLR) Low density lipoprotein (LDL) cholesterol in higher than normal from birth No cure but there is effective management and treatment How common is FH? Frequency from 1/500 to 1/200 Similar frequency to juvenile onset diabetes How is FH treated? Referral to specialist secondary care services High intensity statins Lifestyle modification Substantial increase in premature CHD risk 120,000 to 320,000 affected in the UK 50% reduction in LDL-C & 37% reduction in CHD mortality

FH natural history Age (years) % CHD % CHD <30 5 0 30-39 22 2 40-49 48 7 50-59 80 51 60-69 100 75 Slack J. Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states. The Lancet 1969; 294(7635): 1380-2.

Familial Hypercholesterolaemia Case Ascertainment Tool Clinical Practice Research Datalink (CPRD) 2.9 million patients with cholesterol recorded (including 5050 confirmed FH cases) Developed risk Prediction Algorithm determines probability a patient has FH Nine diagnostic indicators (including cholesterol, family history, secondary causes, age, gender, triglycerides, statins prescribing) MODEL COMPARISONS AUC c-statistic (95% Confidence Interval) Primary Analysis Model 1: TC > 7.5 mmol/l or LDL cholesterol > 4.9 mmol/l 0.556 (0.527 0.587) 1 Model 2: NICE/Simon-Broome Criteria 0.749 (0.735 0.763) 2 Model 3: Dutch Lipid Clinic Criteria 0.737 (0.723 0.752) Model 4: FAMCAT 0.860 (0.848 0.871) Weng SF, Kai J, Andrew Neil H, Humphries SE, Qureshi N. Improving identification of familial hypercholesterolaemia in primary care: Derivation and validation of the familial hypercholesterolaemia case ascertainment tool (FAMCAT). Atherosclerosis 2015; 238(2): 336-43.

Translation of FAMCAT to UK General Practice: FH Case-Finder Requirements: Direct extraction of General Practice patient data based on NHS Read Codes/SNOMED CT Algorithm ranking of probability of FH from most probable to least probable Mail-merge from patient level data Auditing feature for feedback to GPs on patients assessed and screened Display family history recording Display prescribing of statins

CHART Summary Sheet

Patient Level Data: Named (Identifiable version at practice); Pseudo-anonymised for researchers/ccgs

Pilot Data Extraction from Four General Practices Practice Total Patients Adults > 16 years Adults > 16 years & TC/LDL Recorded High Probability FH 1 (East Midlands) 8,499 6,587 3,009 154 2 (East Midlands) 5,965 4,829 2,268 113 3 (East Midlands) 12,885 10,710 6,222 237 4 (North London) 6,581 5,526 3,082 271 Total 33,930 27,652 14,581 775 Proportion of GP Population Requires Assessment: 775/33,930 = 2.3% Ranking system in tool will prioritise patients with highest probability of FH

In Development: Mobile Application

To Summarise: Shown that FAMCAT can accurate predict FH better than previous diagnostic criteria Developed an implementation to practice pathway and toolkit for general practice Developed web-based tool for non-uk audiences Successfully extracted data using the toolkit in four practices (3 East Midlands, 1 North London) Going Forward: Assess the clinical utility of the FAMCAT prospectively in multi-centre study Assess diagnostic accuracy using a gold standard genetic diagnosis: next generation sequencing Full trial against usual care: cluster RCT design Full economic evaluation of FAMCAT to determine cost-effectiveness

Acknowledgements: Professors Nadeem Qureshi & Joe Kai Division of Primary Care University of Nottingham Professor Steve Humphries Centre for Cardiovascular Genetics University College London Professor Andrew Neil Centre for Diabetes, Endocrinology & Metabolism University of Oxford Dr Jon Robinson, Ms Miriam Lemar, Ms Barbara Heyes, & Mr Tim Morell PRIMIS Ltd. University of Nottingham Professor Heather Wharrad & Mr Mike Taylor Health and E-Learning Media Team University of Nottingham Interested in FH? Contact FAMCAT Study Team stephen.weng@nottingham.ac.uk School for Primary Care Research This project was funded by the Nottingham CCG Programme Grant Development Award and supported by the School for Primary Care Research. The views expressed are those of the author(s) and not necessarily those of the CCG, NHS, the NIHR or the Department of Health.